Acquired Angioedema Due to C1 Inhibitor Deficiency Clinical Presentation
- Author: Amanda T Moon, MD; Chief Editor: William D James, MD more...
Apart from negative family history and age of onset, acquired angioedema cannot be distinguished clinically from hereditary angioedema.
Patients with acquired angioedema typically report no family history and onset is most commonly after the fourth decade.
Patients with acquired angioedema, similar to hereditary angioedema, report recurrent episodes of subcutaneous or submucosal edema at various locations, usually lasting 48-72 hours, but they can persist for up to 5 days in rare occasions. The edema is usually unresponsive to antihistamine therapy. The frequency of attacks is unpredictable and varies widely among affected individuals, as well as in the same individual.[7, 8]
Angioedema symptoms are referable to 3 prominent sites: subcutaneous tissues (eg, face, hands, arms, legs, genitals, buttocks); abdominal organs (eg, stomach, intestines, bladder), which may manifest as nausea, vomiting, and/or colicky pain and mimic a surgical emergency; and the upper airway (eg, larynx), which may result in laryngeal edema.
The most common reported symptom is nonpitting, nonpruritic cutaneous swelling of face and extremities.
Occasionally, acquired angioedema patients may experience heat and pain in the affected areas. Other symptoms of acquired angioedema may be related to underlying disorders, such as lymphoproliferative malignancies or connective tissue disease.
The clinical presentation is not distinguishable from hereditary angioedema. Physical signs include overt, noninflammatory swelling of the skin and mucous membranes. Although urticaria does not usually occur, occasionally, erythema or mild urticarial eruptions may precede the edema.
When looking at reports of different rates of recurrence at specific sites, hereditary angioedema has a tendency to present with more extremity involvement than does acquired angioedema, which presents more with face involvement than limb involvement. Acute abdominal pain due to edema of the gastrointestinal mucosa is less reported in acquired angioedema (30-50%) when compared with hereditary angioedema, in which it is reported in up to 80%.[7, 8]
Caldwell JR, Ruddy S, Schur PH, Austen KF. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol. 1972. 1:39-52.
Caballero T, Baeza ML, Cabañas R, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol. 2011. 21(5):333-47; quiz follow 347. [Medline].
Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med. 2009 Feb. 15(2):69-78. [Medline].
Cugno M, Castelli R, Cicardi M. Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. Autoimmun Rev. 2008 Dec. 8(2):156-9. [Medline].
Castelli R, Wu MA, Arquati M, Zanichelli A, Suffritti C, Rossi D, et al. High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibtor deficiency. Br J Haematol. 2016 Jan 5. [Medline].
Banerji A, Sheffer AL. The spectrum of chronic angioedema. Allergy Asthma Proc. 2009 Jan-Feb. 30(1):11-6. [Medline].
Bouillet-Claveyrolas L, Ponard D, Drouet C, Massot C. Clinical and biological distinctions between type I and type II acquired angioedema. Am J Med. 2003 Oct 1. 115(5):420-1. [Medline].
Engel R, Rensink I, Roem D, Brouwer M, Kalei A, Perry D, et al. ELISA to measure neutralizing capacity of anti-C1-inhibitor antibodies in plasma of angioedema patients. J Immunol Methods. 2015 Aug 28. [Medline].
Bork K. An evidence based therapeutic approach to hereditary and acquired angioedema. Curr Opin Allergy Clin Immunol. 2014 Aug. 14 (4):354-62. [Medline].
Zegers IH, Aaldering KN, Nieuwhof CM, Schouten HC. Non-myeloablative allogeneic stem cell transplantation: a new treatment option for acquired angioedema?. Neth J Med. 2015 Oct. 73 (8):383-5. [Medline].
Levi M, Hack CE, van Oers MH. Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. Am J Med. 2006 Aug. 119(8):e3-5. [Medline].
Ziakas PD, Giannouli S, Psimenou E, Evangelia K, Tzioufas AG, Voulgarelis M. Acquired angioedema: a new target for rituximab?. Haematologica. 2004 Aug. 89(8):ELT13. [Medline].
Klossowski N, Braun SA, von Gruben V, Losem C, Plewe D, Homey B, et al. [Acquired angioedema with C1-INH deficiency and accompanying chronic spontaneous urticaria in a patient with chronic lymphatic B cell leukemia]. Hautarzt. 2015 Sep 3. [Medline].
Desai HG, Shah SS. Recurrent intestinal obstruction with acquired angio-oedema, due to C1-esterase inhibitor deficiency. J Assoc Physicians India. 2014 Jun. 62 (6):524-5. [Medline].
Kaur R, Williams AA, Swift CB, Caldwell JW. Rituximab therapy in a patient with low grade B-cell lymphoproliferative disease and concomitant acquired angioedema. J Asthma Allergy. 2014. 7:165-7. [Medline].
Dreyfus DH, Na CR, Randolph CC, Kearney D, Price C, Podell D. Successful rituximab B lymphocyte depletion therapy for angioedema due to acquired C1 inhibitor protein deficiency: association with reduced C1 inhibitor protein autoantibody titers. Isr Med Assoc J. 2014 May. 16 (5):315-6. [Medline].
Rottem M, Mader R. Successful use of etanercept in acquired angioedema in a patient with psoriatic arthritis. J Rheumatol. 2010 Jan. 37(1):209. [Medline].